NYSEMKT: PHGEBiomx Inc Stock Ownership - Who owns Biomx?
Insider buying vs selling
Have Biomx Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Reuven Yeganeh | Director | 2026-03-17 | 530,000 | $2.00 | $1.06MBuy |
| Reuven Yeganeh | Director | 2026-03-17 | 530,000 | $5.00 | $2.65MSell |
| Reuven Yeganeh | Director | 2026-03-16 | 450,000 | $2.00 | $900.00kBuy |
| Reuven Yeganeh | Director | 2026-03-16 | 450,000 | $5.00 | $2.25MSell |
| Reuven Yeganeh | Director | 2026-03-13 | 370,000 | $2.00 | $740.00kBuy |
| Reuven Yeganeh | Director | 2026-03-13 | 370,000 | $5.00 | $1.85MSell |
| Reuven Yeganeh | Director | 2026-03-12 | 300,000 | $5.00 | $1.50MSell |
| Reuven Yeganeh | Director | 2026-03-11 | 300,000 | $2.00 | $600.00kSell |
PHGE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when PHGE insiders and whales buy or sell their stock.
PHGE Shareholders
What type of owners hold Biomx Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Orbimed Israel Biofund GP Limited Partnership | 135.75% | 13,773,653 | $2.52M | Insider |
| Erez Chimovits | 45.60% | 4,626,978 | $846.74k | Insider |
| Chidozie Ugwumba | 29.54% | 2,997,025 | $548.46k | Insider |
| James E. Flynn | 24.58% | 2,494,108 | $456.42k | Insider |
| Takeda Pharmaceutical Co Ltd | 24.35% | 2,470,935 | $452.18k | Insider |
| Jonas Grossman | 20.50% | 2,080,217 | $380.68k | Insider |
| Fibrosis Foundation Cystic | 17.62% | 1,787,758 | $327.16k | Insider |
| Gbolahan Amusa | 2.59% | 262,871 | $48.11k | Insider |
| Kerry Propper | 2.57% | 260,771 | $47.72k | Insider |
| Deerfield Management Company LP | 1.29% | 131,272 | $24.02k | Institution |
PHGE vs Biotech Stocks
Biomx Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.